EyePoint Pharmaceuticals announced the appointment of leading global ophthalmologists to its Scientific Advisory Board, SAB. The SAB additions include Usha Chakravarthy, M.B.B.S., Ph.D.; Allen Ho, M.D. FACS FASRS, and Frank Holz, M.D., F.E.B.O., F.A.R.V.O. Additionally, the Company announced that the U.S. Food and Drug Administration has conditionally accepted the trade name, DURAVYUTM for the Company’s lead product candidate, EYP-1901.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint reports inducement grants under Nasdaq listing rule
- Bad News for Eyepoint Pharma Stock: This New Risk Has Been Added
- EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
- EyePoint expects cash to fund operations through Phase 3 trial data in 2026
